Secretion pattern of the rat liver macrophage population following activation with liposomal muramyl dipeptide in vivo and in vitro.
Incubation of rat liver macrophages in vitro with free or liposome-encapsulated muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-isoglutamine; MDP) resulted in a rapid but transient release of tumor necrosis factor-alpha (TNF-alpha), followed by a slow, steady release of nitric oxide (NO) and prostaglandin (PG) E. The secretion pattern induced in situ was determined by isolating the liver macrophages at 2, 12, 24, 48, and 72 h after injection of liposomal MDP and measuring the amounts of products secreted in a 24-h period following isolation. TNF-alpha secretion was detected only in macrophages isolated as early as 2 h after injection of liposomal MDP and not at later time points. Considerable heterogeneity was observed among macrophages of different size: For example, the large-sized cells were far more potent in TNF secretion than the smaller cells. Nitric oxide secretion, on the other hand, was maintained over a full 24-h period following MDP administration and was virtually independent of macrophage size. With regard to PGE release, similar to TNF-alpha secretion, considerable differences in secretory activity between cells of different size were observed. Also in this case the large cells were several times more active than the small cells. In contrast to TNF, however, PGE secretion could be detected up to 24 h after injection of liposomal MDP. These findings support the notion that the development and maintenance of the activated state of liver macrophages, induced by immunomodulators such as liposomal MDP, are under the control of a complex network of regulatory functions and that multiple secretory products play a role in the observed macrophage-mediated cytotoxicity.
Hoedemakers
R M
RM
Groningen Institute for Drug Studies, State University Groningen, The Netherlands.
Morselt
H W
HW
Scherphof
G L
GL
Daemen
T
T
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D002478:Cells, Cultured; D004337:Drug Carriers; D008081:Liposomes; D008099:Liver / Q000166:cytology; D008262:Macrophage Activation / Q000187:drug effects*; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism; D011458:Prostaglandins E / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D004337:Drug Carriers; D008081:Liposomes; D011458:Prostaglandins E; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D000119:Acetylmuramyl-Alanyl-Isoglutamine